PMID- 21635552
OWN - NLM
STAT- MEDLINE
DCOM- 20110808
LR  - 20181201
IS  - 1600-0463 (Electronic)
IS  - 0903-4641 (Linking)
VI  - 119
IP  - 7
DP  - 2011 Jul
TI  - Prognostic significance of epidermal growth factor receptor and vascular 
      endothelial growth factor receptor in colorectal adenocarcinoma.
PG  - 449-59
LID - 10.1111/j.1600-0463.2011.02752.x [doi]
AB  - The purpose of this study was to evaluate the association between the expression 
      of growth factors and the clinicopathological variables of colorectal 
      adenocarcinoma. Immunohistochemistry and fluorescence in situ hybridization 
      (FISH) were used to evaluate the amplification and expression of epidermal growth 
      factor receptor (EGFR), vascular endothelial growth factor (VEGF), VEGF-D, VEGF 
      receptor (VEGFR)-2, VEGFR-3, transforming growth factor (TGF)-beta1, and 
      insulin-like growth factor-1 receptor (IGF-1R) in a tissue microarray of 292 
      colorectal adenocarcinomas. The expression of EGFR, VEGF, VEGF-D, VEGFR-2 and 
      VEGFR-3 was detected in 5.1%, 10.0%, 6.8%, 5.2%, and 57.2%. EGFR expression was 
      associated with angioinvasion (p < 0.05) and lymph node metastasis (p < 0.005). 
      VEGFR-3 expression was higher in the rectum than in the colon (p < 0.05). VEGF 
      expression correlated with VEGF-D (p < 0.05) and VEGFR-3 (p < 0.005) expression, 
      while VEGF-D expression showed no significant association with VEGFR-2 or 
      VEGFR-3. EGFR amplification was present in 10.6% and was not associated with EGFR 
      protein expression. VEGFR-2 and VEGFR-3 expression levels were related to poor 
      patient survival. Stage, perineural invasion, and lymph node metastasis were 
      independent prognostic factors based on a Cox analysis. VEGFR-2 and VEGFR-3 
      expression are markers of a poor prognosis in patients with surgically resected 
      colorectal adenocarcinoma, whereas EGFR has a minor influence.
CI  - (c) 2011 The Authors. APMIS (c) 2011 APMIS.
FAU - Kim, Jung Yeon
AU  - Kim JY
AD  - Department of Pathology, Inje University Sanggye Paik Hospital, Seoul, Korea. 
      jykimpath@paik.ac.kr
FAU - Bae, Byung-Noe
AU  - Bae BN
FAU - Kwon, Ji Eun
AU  - Kwon JE
FAU - Kim, Hyun-Jung
AU  - Kim HJ
FAU - Park, Kyeongmee
AU  - Park K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110425
PL  - Denmark
TA  - APMIS
JT  - APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
JID - 8803400
RN  - 0 (Transforming Growth Factor beta1)
RN  - 0 (Vascular Endothelial Growth Factor D)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Receptor, IGF Type 1)
RN  - EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-2)
RN  - EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-3)
SB  - IM
MH  - Adenocarcinoma/drug therapy/*metabolism/mortality
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cell Proliferation
MH  - Colorectal Neoplasms/drug therapy/*metabolism/mortality
MH  - Disease Progression
MH  - ErbB Receptors/*biosynthesis/genetics
MH  - Female
MH  - Fluorescent Antibody Technique
MH  - Gene Expression
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Microarray Analysis
MH  - Middle Aged
MH  - Prognosis
MH  - Receptor, IGF Type 1/biosynthesis/genetics
MH  - Survival Rate
MH  - Transforming Growth Factor beta1/biosynthesis/genetics
MH  - Vascular Endothelial Growth Factor D/*biosynthesis/genetics
MH  - Vascular Endothelial Growth Factor Receptor-2/*biosynthesis/genetics
MH  - Vascular Endothelial Growth Factor Receptor-3/*biosynthesis/genetics
EDAT- 2011/06/04 06:00
MHDA- 2011/08/09 06:00
CRDT- 2011/06/04 06:00
PHST- 2011/06/04 06:00 [entrez]
PHST- 2011/06/04 06:00 [pubmed]
PHST- 2011/08/09 06:00 [medline]
AID - 10.1111/j.1600-0463.2011.02752.x [doi]
PST - ppublish
SO  - APMIS. 2011 Jul;119(7):449-59. doi: 10.1111/j.1600-0463.2011.02752.x. Epub 2011 
      Apr 25.